Monte Rosa Therapeutics(NASDAQ) GLUE

Market Cap$1.92B

Since IPO (2021)+7%

5 Year-8%

1 Year+306%

1 Month-6%

$16.37

-27.82%

-6.31Today

Monte Rosa Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 22.68	2026-07-30

Monte Rosa Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.52%	USD 23.03	2026-07-23
1 month	-6.28%	USD 24.20	2026-06-30
3 month	+20.64%	USD 18.80	2026-05-01
Year to date	+44.64%	USD 15.68	2025-12-31
1 year	+306.45%	USD 5.58	2025-07-30
3 year	+220.79%	USD 7.07	2023-07-31
5 year	-7.5%	USD 24.52	2021-07-30
Since inception	+7.08%	USD 21.18	2021-06-24

Monte Rosa Therapeutics Financials at a Glance

Market Cap

$1.92B

Revenue (TTM)

$42.95M

Net Income (TTM)

-$130.01M

EPS (TTM)

-$1.63

P/E Ratio

-13.93

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$16.37

Volume

5,682,710.005

Open

$15.47

Price

$16.37

Volume

5,682,710.005

Open

$15.47

Previous Close

$22.68

Daily Range

$14.87 - $16.60

52-Week Range

$4.12 - $25.77

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$16.37

Volume

5,682,710.005

Open

$15.47

Previous Close

$22.68

Daily Range

$14.87 - $16.60

52-Week Range

$4.12 - $25.77

Estimated Earnings Date

Aug 6, 2026

GLUE News

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Jonathan PoncianoJun 29, 2026

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Jonathan PoncianoApr 21, 2026

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

Motley Fool Markets TeamAug 7, 2025

GLUE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Monte Rosa Therapeutics

Monte Rosa makes medicines that help the body destroy harmful proteins. These drugs target specific parts of cells that cause serious diseases. They help patients with cancer and immune system problems.

Editing the Body's Proteins

MRT-6160: Small molecule designed to destroy the VAV1 protein to treat immune system diseases like multiple sclerosis.
MRT-8102: Treatment targeting the NEK7 protein to reduce inflammation in patients with heart disease or gout.
MRT-2359: Drug targeting the GSPT1 protein to stop growth in certain prostate cancer cells.
QuEEN Engine: Proprietary technology using artificial intelligence to design new "molecular glue" medicines.

Winning Big with Big Pharma

Partnered with Novartis in October 2024 to develop and sell VAV1-directed drugs.
Signed a deal with Roche in October 2023 to find treatments for cancer and brain diseases.
Agreed to a new partnership with Novartis in September 2025 for immune and inflammatory programs.
Received $150 million upfront from Novartis to fund Phase 2 clinical studies.

Precision Glue Technology

The company uses a system called QuEEN to target proteins once considered undruggable, meaning they were hard to reach with standard drugs. This platform uses geometric deep learning to design molecules that reprogram the body's natural protein destruction mechanisms.

Checking the Ledger

Revenue was $2.8 million in Q4 2025, down 95.4% from $60.6 million in Q4 2024.
Operating income was -$49.7 million in Q4 2025, down from $13 million in Q4 2024 (turned negative — worsened).
Net income reached -$46.1 million in Q4 2025, down from $13.4 million in Q4 2024 (turned negative — worsened).
Market cap hit $1.0 billion in Q4 2025, up 141% from $426.4 million in Q4 2024.
Free cash flow was -$43.8 million in Q4 2025, down 134% year-over-year (turned negative — worsened).

Bottom Line

Monte Rosa has transitioned from an early-stage researcher to a clinical-stage developer with major global partners. Its focus on molecular glues allows it to tackle diseases that traditional drugs often miss.

AI Generated • Apr 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

150

CEO

Markus Warmuth, MD

Website

www.monterosatx.com

Headquarters

Boston, MA 02210, US

GLUE Financials

Key Financial Metrics (TTM)

Gross Margin

95.28%

Operating Margin

-345.21%

Net Income Margin

-302.69%

Return on Equity

-40.99%

Return on Capital

-19.91%

Return on Assets

-17.65%

Earnings Yield

-7.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.92B

Shares Outstanding

84.48M

Volume

5.68M

Avg. Volume

1.20M

Financials (TTM)

Gross Profit

$40.92M

Operating Income

-$148.28M

EBITDA

-$123.54M

Operating Cash Flow

-$14.68M

Capital Expenditure

-$4.98M

Free Cash Flow

-$19.66M

Cash & ST Invst.

$666.22M

Total Debt

$39.06M

Monte Rosa Therapeutics Performance Analysis

Monte Rosa Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 75,622,000	N/A
2025	2025-12-31	USD 123,672,000	63.5%

Monte Rosa Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-72.7%
Q3	2025-09-30	-45.0%
Q4	2025-12-31	-78.2%
Q1	2026-03-31	51.4%

Monte Rosa Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.30	44.6%
2023	2023-12-31	USD -2.63	14.6%
2024	2024-12-31	USD -0.98	-62.7%
2025	2025-12-31	USD -0.47	-52.7%

Monte Rosa Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-126.3%
Q3	2025-09-30	-120.0%
Q4	2025-12-31	-112.1%
Q1	2026-03-31	2.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$4.21M

-95.0%

Gross Profit

$2.18M

-97.4%

Gross Margin

51.81%

N/A

Market Cap

$1.92B

N/A

Market Cap/Employee

$12.77M

N/A

Employees

150

N/A

Net Income

-$44.50M

-194.9%

EBITDA

-$42.42M

-185.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$666.22M

+104.3%

Total Debt

$39.06M

-6.7%

Accounts Receivable

$4.61M

+227.3%

Inventory

$0.00

N/A

Long Term Debt

$34.58M

-9.0%

Short Term Debt

$4.48M

+16.0%

Return on Assets

-17.65%

N/A

Return on Invested Capital

-22.28%

N/A

Free Cash Flow

-$39.24M

+16.7%

Operating Cash Flow

-$37.37M

+17.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

DAWNDay One Biopharmaceuticals, Inc.

DAWNDay One Biopharmaceuticals, Inc.$21.53+0.00%

VIRVir Biotechnology, Inc.

VIRVir Biotechnology, Inc.$8.56-3.83%

AVBPArriVent BioPharma, Inc.

AVBPArriVent BioPharma, Inc.$30.09-1.86%

MGTXMeiraGTx Holdings plc

MGTXMeiraGTx Holdings plc$11.81-1.42%

REPLReplimune Group, Inc.

REPLReplimune Group, Inc.$11.22+107.39%

TBPHTheravance Biopharma Inc

TBPHTheravance Biopharma Inc$16.87+0.10%

GERNGeron Corporation

GERNGeron Corporation$1.27-5.22%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AMZNAmazon

AMZNAmazon$271.35+0.15%

FCUVFocus Universal

FCUVFocus Universal$14.31+6.61%

AAPLApple

AAPLApple$305.32-0.08%

NVDANvidia

NVDANvidia$200.37+0.03%

INTCIntel

INTCIntel$92.43+0.01%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$24.67-0.09%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.28+0.01%

Questions About GLUE

What is the current price of Monte Rosa Therapeutics?

Monte Rosa Therapeutics is trading at $16.25 per share.

What is the 52-week range for Monte Rosa Therapeutics?

Over the past 52 weeks, Monte Rosa Therapeutics has traded between $4.12 and $25.77.

How much debt does Monte Rosa Therapeutics have?

As of the most recent reporting period, Monte Rosa Therapeutics reported total debt of $39.06M.

How much cash does Monte Rosa Therapeutics have on hand?

Monte Rosa Therapeutics reported $159.86M in cash and cash equivalents in its most recent financial results.

What is Monte Rosa Therapeutics’s dividend yield?

Monte Rosa Therapeutics does not currently have a dividend yield.

Monte Rosa Therapeutics(NASDAQ) GLUE

Monte Rosa Therapeutics Financials at a Glance

GLUE News

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

GLUE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Monte Rosa Therapeutics

Editing the Body's Proteins

Winning Big with Big Pharma

Precision Glue Technology

Checking the Ledger

Bottom Line

GLUE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Monte Rosa Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GLUE

What is the current price of Monte Rosa Therapeutics?

What is the 52-week range for Monte Rosa Therapeutics?

How much debt does Monte Rosa Therapeutics have?

How much cash does Monte Rosa Therapeutics have on hand?

What is Monte Rosa Therapeutics’s dividend yield?

Premium Investing Services